Haolan Lu
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 21
- Colorectal Cancer Treatments and Studies 7
- Peptidase Inhibition and Analysis 7
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 3
-
- Lung Cancer Treatments and Mutations 6
- Prostate Cancer Treatment and Research 3
- Co-authors
- Jean-Marie Cuillerot (2 shared papers)Thomas J. Lynch (3 shared papers)Fabrice Barlési (2 shared papers)Alexander Luft (1 shared paper)Martin Sebastian (1 shared paper)Martin Reck (1 shared paper)Raju Titus Chacko (1 shared paper)Igor Bondarenko (1 shared paper)
- Journals
- Journal of Clinical Oncology (16 papers)The Oncologist (2 papers)Journal of Thoracic Oncology (2 papers)Cancer Research (2 papers)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Haolan Lu
33 papers receiving 1.7k citations
Haolan Lu's Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 1.1k
- Immunology 435
- Pulmonary and Respiratory Medicine 392
- Cancer Research 89
- Statistics and Probability 52
Countries citing papers authored by Haolan Lu
This map shows the geographic impact of Haolan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haolan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haolan Lu more than expected).
Fields of papers citing papers by Haolan Lu
This network shows the impact of papers produced by Haolan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haolan Lu. The network helps show where Haolan Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Haolan Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study Hit paper breakdown → | 2012 | 839 |
| 2 | Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). Hit paper breakdown → | 2022 | 136 |
| 3 | 2021 | 100 | |
| 4 | 2005 | 74 | |
| 5 | 2021 | 59 | |
| 6 | 2007 | 54 | |
| 7 | 2022 | 53 | |
| 8 | 2008 | 43 | |
| 9 | 2009 | 40 | |
| 10 | 2017 | 37 | |
| 11 | 2023 | 32 | |
| 12 | 2007 | 29 | |
| 13 | 2023 | 28 | |
| 14 | 2022 | 27 | |
| 15 | 2000 | 26 | |
| 16 | 2009 | 19 | |
| 17 | 2013 | 16 | |
| 18 | 2007 | 11 | |
| 19 | 2022 | 10 | |
| 20 | 2018 | 10 |
About Haolan Lu
Haolan Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Pathology and Forensic Medicine and Surgery, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Peptidase Inhibition and Analysis (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers), Protein Degradation and Inhibitors (5 papers), Lymphoma Diagnosis and Treatment (4 papers), CAR-T cell therapy research (3 papers) and Prostate Cancer Treatment and Research (3 papers). The work is most often cited by research in Oncology (1.1k citations), Immunology (435 citations), Pulmonary and Respiratory Medicine (392 citations), Cancer Research (89 citations) and Statistics and Probability (52 citations). Haolan Lu has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Jean-Marie Cuillerot, Thomas J. Lynch, Fabrice Barlési, Alexander Luft, Martin Sebastian, Martin Reck, Raju Titus Chacko, Igor Bondarenko, Piotr Serwatowski and Joel W. Neal. Their work appears in journals such as Journal of Clinical Oncology, The Oncologist, Journal of Thoracic Oncology, Cancer Research and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.